Sale of SFL Group
7 March 2022 – The two former shareholders, Shayesteh Fürst-Ladani und Walter Fürst, have sold 100% of the shares in all SFL group companies with their registered seats in Switzerland (SFL Regulatory Affairs & Scientific Communication GmbH und SFL Pharma GmbH), Germany (SFL Pharmaceuticals Deutschland GmbH), Austria (SFL Regulatory Services GmbH), and the UK (SFL Regulatory Affairs Consulting Ltd) to US-based clinical research organization (CRO) Veristat.
SFL Group is a leading consulting firm providing integrated solutions to pharmaceutical, biotech, and Medtech companies in the areas of drug development, regulatory affairs, and clinical trials, as well as combined drug-medicine products.
Walder Wyss has advised as lead transaction counsel the two former shareholders, Shayesteh Fürst-Ladani und Walter Fürst, on the Swiss law aspects of the transaction. The team included Stefan Knobloch (Partner, Corporate/M&A), Dario Galli (Associate, Corporate/M&A), and Marina Beeler (Junior Associate, Corporate/M&A).